Description
Sitagliptinisananti-diabetic/anti-hyperglycemiccompoundthatinhibitsdipeptidylpeptidase4(DPP4);sitagliptinalsoexhibitsantioxidativeandcardioprotectivebenefit.Sitagliptindecreasesreleaseoflactatedehydrogenase,malondialdehyde,andcreatinekinaseMB,andincreaseslevelsofglutathioneperoxidase,glucagon-likepeptide1(GLP-1),andsuperoxidedismutase;thiscompoundalsodecreasesexpressionofcaspases3and9,causingdecreasesincardiacapoptosisandimprovementsincardiacfunction.Inhypertensiverats,sitagliptinincreaseslevelsofGLP-1,theGLP-1receptor,cAMP,andeNOSandalsoincreasesactivationofAMPK,improvingvascularendothelialfunction.
References
ChangG,ZhangP,YeL,etal.Protectiveeffectsofsitagliptinonmyocardialinjuryandcardiacfunctioninanischemia/reperfusionratmodel.EurJPharmacol.2013Oct15;718(1-3):105-13.PMID:24041927.
KubotaY,MiyamotoM,TakagiG,etal.Thedipeptidylpeptidase-4inhibitorsitagliptinimprovesvascularendothelialfunctionintype2diabetes.JKoreanMedSci.2012Nov;27(11):1364-70.PMID:23166419.
LiuL,LiuJ,WongWT,etal.Dipeptidylpeptidase4inhibitorsitagliptinprotectsendothelialfunctioninhypertensionthroughaglucagon-likepeptide1-dependentmechanism.Hypertension.2012Sep;60(3):833-41.PMID:22868389.
WagetA,CabouC,MasseboeufM,etal.PhysiologicalandpharmacologicalmechanismsthroughwhichtheDPP-4inhibitorsitagliptinregulatesglycemiainmice.Endocrinology.2011Aug;152(8):3018-29.PMID:21673098.
